VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005955/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd. and ChemoCentryx, Inc., today announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for avacopan for the treatment of patients with ANCA-associated vasculitis (granulomatosis with polyangitis (GPA) and microscopic polyangiitis (MPA)), a group of rare and severe autoimmune diseases with high need for targeted therapies.
If approved, avacopan would be the first orally administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Data from the global pivotal phase-III ADVOCATE trial demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compared to the prednisone group. In the trial, the avacopan group also showed significantly lower glucocorticoid toxicity, greater improvement in kidney function and greater improvement in health-related quality of life measures compared to the prednisone group.
The EMA will review the application under the centralized marketing authorization procedure. If approved avacopan would receive marketing authorization in all member states of the European Union (EU), as well as in Iceland, Liechtenstein and Norway. Approval is expected H2, 2021.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis.
ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
About ADVOCATE and ANCA-Associated Vasculitis
The ADVOCATE trial of avacopan was a global double-blind double-dummied Phase III trial of 331 patients with ANCA-associated vasculitis (ANCA vasculitis) in 20 countries.
ANCA vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as a major target. Treatment for ANCA vasculitis consists of courses of immuno-suppressants (cyclophosphamide or rituximab), combined with high-dose and often prolonged use of glucocorticoids which can be associated with significant adverse events. ANCA vasculitis is relapsing and remitting long term condition and patients are at risk of cumulative organ damage.
Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1. By precisely blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment, C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA vasculitis. Avacopan therapy was designed to deliver effective control of the inflammatory vasculitic process and prevent relapse while also reducing the risk of treatment related damage. Moreover, avacopan’s selective inhibition of only the C5aR1 leaves the beneficial C5a l pathway through the C5L2 receptor functioning normally.
ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted avacopan orphan-drug designation for ANCA-associated Vasculitis, C3G and atypical hemolytic uremic syndrome. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA Vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G.
ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding whether avacopan will be approved for the treatment of ANCA vasculitis. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC on March 10, 2020 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Global Head Corporate Communications
+41 79 957 96 73
Head of Investor Relations
+41 58 851 66 90
Susan M. Kanaya
Executive Vice President
Chief Financial and Administrative Officer
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cazoo Launches in France and Germany1.12.2021 13:27:00 CET | Press release
Cazoo (NYSE: CZOO), Europe’s leading online car retailer, which makes buying and selling a car as simple and seamless as ordering any other product online, today announced that it has now launched its service in both France and Germany, delivering better selection, value, transparency, convenience and peace of mind to consumers in mainland Europe when buying their next car. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005572/en/ (Photo: Business Wire) Cazoo owns and reconditions its cars to the highest standard before offering them for delivery in just a few days and has hundreds of cars available in France (www.cazoo.com/fr) and Germany (www.cazoo.com/de). With customers able to purchase a car entirely online and have it delivered directly to their door, Cazoo has been referred to as the ‘Amazon of the used car market’. Cazoo customers can review high quality, 360-degree images from the comfort of their home as well
Finsbury Glover Hering and Sard Verbinnen & Co. Complete Merger, Creating Global Strategic Communications Leader1.12.2021 12:30:00 CET | Press release
Following their announcement on October 13, 2021, Finsbury Glover Hering and Sard Verbinnen & Co. (“SVC”) have completed their merger to create the world’s leading strategic communications firm advising clients in navigating critical opportunities and challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005402/en/ The firm brings together over 1,000 communications professionals, operating from 25 offices in Asia, Europe, the Middle East and the United States, including its global headquarters in New York. The new firm is a leader in all aspects of strategic communications, including government affairs, corporate reputation, crisis management and transformation and change, as well as the leading force in financial communications worldwide. Its professionals have deep sector knowledge within rapidly growing industries, such as Health, Tech, Food and Agriculture and Renewable Energy, as well as expertise in Diversit
Wella Company Celebrates Its First Year as an Independent Company by Exceeding Growth Targets, Introducing Breakthrough Innovation and Broadening Leadership Capabilities1.12.2021 12:00:00 CET | Press release
Wella Company, a global leader in the $100 billion beauty industry, today celebrates its one-year anniversary as a stand-alone company. Wella Company has a top professional and retail hair, beauty tech and nail portfolio of iconic brands including Wella Professionals, Clairol, OPI, Nioxin, Sebastian Professional and ghd. The Company, founded in Germany in 1880, returned to independent operating status on December 1, 2020, led by global investment firm Kohlberg Kravis and Roberts (“KKR”) investing a majority-equity stake, which they have twice increased over the past year. Wella Company emerged in the midst of the global COVID-19 pandemic, during which almost the entire professional salon industry – the company’s core customer base – was in lockdown. Despite this challenging global environment, the company set its growth strategy, focused on building the operating foundation for stand-alone success, and hired nearly 1,100 people across the globe, including a roster of top beauty, retail
Pioneer Completes Acquisition of Kodoku Studios1.12.2021 10:59:00 CET | Press release
Pioneer Media Holdings Inc. (“Pioneer” or the “Company”) is pleased to announce that, further to its news release dated October 28, 2021, it has completed its acquisition of Kodoku Studios Limited (“Kodoku”). Kodoku is a studio based in London, England, in the business of developing and publishing NFT (or non-fungible token) games. Its current focus is “The Pit,” a platform for gamers to stake their NFTs, which also allows gamers to attempt to increase the inherent value of their NFTs through “NFT warfare” in a “player vs. player” (PVP) gaming arena, anticipated to launch December 3, 2021. Hewie Rattray, CEO of Kokoku commented, “I am positively thrilled by the acquisition of Kodoku by Pioneer. We relish the opportunity to exercise our vision in the NFT gaming market under the guidance of such an innovative company. We eagerly anticipate unifying with the Pioneer trajectory as we push the frontiers of the metaverse to new limits.” In consideration of all of the securities of Kodoku, th
ATG to Use Ethical Hackers to Rein in Cybersecurity Challenges in Partnership With YesWeHack1.12.2021 10:00:00 CET | Press release
YesWeHack, Europe’s leading bug bounty platform has partnered with Sweden headquartered ATG, to identify potential vulnerabilities on its exposed assets. ATG provides quality excitement and entertainment through horse betting, sports betting and casino games for approximately 1.4 million customers. ATG is constantly evolving to meet new technology demands, increased data access, faster connections, and new digital channels. It is at the forefront of using digital technology to offer content-rich, personalised, and constantly available entertainment while meeting stricter regulation, digitalisation, and higher customer demands. Like other industries that retain extensive customer data, the sports betting and gambling industry is particularly vulnerable to cyber threats. In addition to the games themselves, ATG maintains databases that contain a wealth of private and financial information. It has payment systems and apps that hackers can target. Meanwhile, one of the most significant cha
Nordic Enterprises Embrace Cloud Services to Improve Customer Experience1.12.2021 10:00:00 CET | Press release
Enterprises in the Nordic region are increasing their spending on public cloud services and digital transformation to improve customer experiences, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2021 ISG Provider Lens™Public Cloud – Services & Solutions Report for the Nordics finds enterprises in the region also increasing cloud spending to expand their product and service portfolios across the globe. In response, public cloud service providers are focused on improving their digital transformation advisory services. Cloud spending in the Nordics has increased across all industry verticals over the last five to six quarters. “Enterprises in the Nordic region have embraced the cloud and emerging digital technologies to become more cost effective and enhance customer experience,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “Companies are also looking for
Amazon Investing in 274 Renewable Energy Projects Globally, Adds 18 New Projects in Europe and U.S.1.12.2021 09:01:00 CET | Press release
Amazon (NASDAQ: AMZN) today announced 18 new utility-scale wind and solar energy projects across the U.S., Finland, Germany, Italy, Spain, and the U.K., totaling 5.6 gigawatts (GW) of procured capacity to date in 2021. Amazon now has 274 renewable energy projects globally and is on a path to power 100% of its business operations with renewable energy by 2025—five years earlier than its original 2030 commitment. These new utility-scale wind and solar projects bring Amazon’s total committed renewable electricity production capacity to more than 12 GW and 33,700 gigawatt hours (GWh) when the projects become fully operational, or electricity output equivalent to powering more than 3 million U.S. homes for a year. The projects will supply renewable energy for Amazon’s corporate offices, fulfillment centers, and Amazon Web Services (AWS) data centers that support millions of customers globally. The projects will also help Amazon meet its commitment to produce the clean energy equivalent of t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom